Implanting the iStent infinite during cataract surgery effectively lowers intraocular pressure (IOP) in patients with mild to moderate primary open-angle glaucoma (POAG), according to a study that provides real-world data on a device originally introduced as a standalone procedure.
Conducted by a single U.S. glaucoma surgeon, the study reviewed records of 36 eyes that underwent phacoemulsification combined with iStent infinite implantation. After 12 months, the mean IOP decreased from 18.2 ± 3.0 mmHg to 14.0 ± 3.4 mmHg, a 23.1% reduction (P < 0.001). In addition, the average number of glaucoma medications dropped by 24.2%, though this change was not statistically significant (P = 0.093).
At one year, 61.1% of eyes achieved more than a 15% IOP reduction, while 55.5% and 25% reached reductions greater than 20% and 40%, respectively. Overall, 80.6% maintained a lower IOP with the same or fewer medications. Adverse events were mild and resolved within a week, with no cases of infection, stent occlusion, or migration. Two eyes required additional glaucoma procedures within a year.
Reference
Vest Z, et al. 1 Year Outcomes of Phacoemulsification with Third-Generation Trabecular Micro-bypass Stent Implantation. Poster presented at: American Glaucoma Society Annual Meeting; February 26–March 2, 2025; Washington, DC.
Related Content
